Increased interleukin-22 (IL-22) level was reported to associate with progression of breast cancer. Regulation of IL-22 in breast cancer still needs to be elucidated. We assessed the effect of giving IL-22 in tumor growth of mice inoculated with 4T1, MCF7 and MDA-MB-231 breast cancer cells. IL-22-producing cells were analyzed in tumor tissues. We also analyzed the impact of giving IL-1β and IL-23 on IL-22 levels in tumor tissues. Giving exogenous IL-22 increased tumor size and intra-tumor Ki-67-positive cells in vivo . IL-22 increased phosphorylated STAT3 level and proliferation of breast cancer cells in vitro , an effect blocked by a STAT3-inhibitor stattic. Endogenous IL-22 mRNA level was up-regulated in tumor tissue, compared with normal mammary tissue. Innate lymphoid cell group 3 (ILC3) is a major producer of IL-22 in 4T1 tumor. Giving IL-1β and/or IL-23 increased cell proliferation in 4T1 tumor, which was reversed by concurrent use of an IL-22 neutralization antibody. IL-1β and IL-23 increased levels of IL-22 mRNA and IL-22-producing ILC3 in 4T1 tumor. Our findings suggest a mechanism for how IL-22 regulates tumor growth in breast cancer, and indicate blocking IL-22 function might reduce IL-1β- and IL-23-induced tumor progression of breast cancer.

Departmental sources Background: Tooth bleaching causes a significant decrease in the bonding strength between the resin and human enamel. Nevertheless, the effects of different antioxidant types on the immediate bonding strength of resin and bleached enamel were significantly different. Therefore, the objective of this study was to compare the effects of 2 antioxidants for enhancing the bond strength of the resin to bleached enamel. Material/Methods: There were 48 enamel blocks performed from 48 recently extracted maxillary central incisors. There were 8 groups: NC (negative control, no bleached specimens restored without antioxidants); NA (no antioxidant, bleached specimens bonded immediately without any antioxidants); SA30, SA60, and SA120 (bleached specimens accepted the management of 10% sodium ascorbate (SA) for 30 minutes, 60 minutes, and 120 minutes, respectively, before restored); PC30, PC60, and PC120 (bleached specimens received treatment of 5% proanthocyanidins (PC) for 30 minutes, 60 minutes, and 120 minutes, respectively, before restored). We measured the micro-tensile bond strength of specimens and used 2-way ANOVA to analyze the data.

No abstract

Background Currently, the standard treatment for locally advanced cervical cancer is concurrent chemoradiation (CCRT). Forty percent of patients present with disease recurrence. This study aims to investigate the feasibility, safety and efficacy of neoadjuvant chemotherapy (NACT) with weekly cisplatin and paclitaxel (TP) followed by CCRT. Methods We are conducting a phase III trial comparing the efficacy and side effects of patients with cervical cancer (FIGO 2018 stage IIB to IVA) who were assigned to four cycles of NACT with cisplatin (40 mg/m2) and paclitaxel (60 mg/m2) weekly followed by CCRT or CCRT alone. In this report, we studied the medium-term effect of 50 patients enrolled in the NACT + CCRT arm. The primary endpoints were the response rate post-NACT and 12 weeks post-CCRT evaluated by MR/CT based on RECIST v 1.1. The secondary endpoints were 3-year OS (overall survival) and PFS (progression-free survival) measured by the Kaplan–Meier method. Results Among 50 patients enrolled in the NACT + CCRT arm, the complete and partial response rates were 10.4% and 68.8%, post-NACT. Twelve weeks after treatment completion, the complete response rate was 72.0%, whereas the total response rate (complete and partial response) was 90.0%. After a median follow-up of 28 months, the 3-year OS rate was 83.9%, and the 3-year PFS rate was 73.6%. NACT response was related to superior PFS and OS compared with NACT nonresponse (P < 0.01). Late AEs were exiguous, while early AEs mainly included myelosuppression and gastrointestinal AEs. Conclusions This study showed a good response rate achieved by dose-dense weekly cisplatin and paclitaxel followed by standard CCRT. The treatment regimen is feasible, as evidenced by the acceptable toxicity of NACT and by the high compliance with radiotherapy. Trial registration Protocol version number and date. Chinese clinical trial registry, ChiCTR1900025327; http://www.chictr.org.cn. Registered 24 August 2019. Retrospectively registered, medresman.org.cn/ChiCTR1900025326. The date recruitment began 01–01-2019.

For a two-dimensional ultra-cold Fermi superfluid with an effective static magnetic impurity, we theoretically investigated the variation of the Yu–Shiba–Rusinov (YSR) bound state in the Bardeen–Cooper–Schrieffer (BCS) to Bose–Einstein condensation (BEC) crossover regime. Within the framework of mean-field theory, analytical results of the YSR bound state energy were obtained as a function of the interaction parameters. First, when the background Fermi superfluid system stays in the weakly interacting BCS regime, we found that the YSR bound state energy is linearly dependent on the gap parameter with its coefficient slightly different from previous results. Second, we discovered re-entrance phenomena for the YSR state and an upper bound of the strength of the interaction between the paired atoms. By carefully analyzing the bound state energy as a function of the interaction parameters, we obtained a phase diagram showing the existence of the YSR state. Finally, we concluded that the re-entrance phenomena and the critical point can be easily experimentally detected through measurement of radio-frequency spectroscopy and density of states using current experimental techniques.